Document is current
Any future updates will be listed below
-
Authors
Gellert, Pascal
Segal, Corrinne V.
Gao, Qiong
López-Knowles, Elena
Martin, Lesley-Ann
Dodson, Andrew
Li, Tiandao https://orcid.org/0000-0003-1650-0555
Miller, Christopher A. https://orcid.org/0000-0003-4266-6700
Lu, Charles
Mardis, Elaine R.
Gillman, Alexa
Morden, James
Graf, Manuela
Sidhu, Kally
Evans, Abigail
Shere, Michael
Holcombe, Christopher
McIntosh, Stuart A.
Bundred, Nigel
Skene, Anthony
Maxwell, William
Robertson, John
Bliss, Judith M.
Smith, Ian
Dowsett, Mitch
,
Johnston, Stephen
Todd, Radha
Horgan, Kieran
Chan, Stephen
Holt, Simon D. H.
Parton, Marina
Laidlaw, Ian
Vaidya, Jayant S.
Irvine, Tracey
Hoar, Fiona
Khattak, Ilyas
Kothari, Ashutosh
Brazil, Lucy
Gallegos, Nicholas
Wheatley, Duncan
Johnson, Tayo
Sparrow, Geoffrey
Ledwidge, Serena
Mortimer, Caroline
Ornstein, Marcus
Ferguson, Douglas
Adamson, Douglas
Cutress, Ramsey
Johnson, Richard
Crowley, Clare
Winters, Zoe
Hamed, Hisham
Burcombe, Russell
Cleator, Susan
Kelleher, Muireann
Roberts, Jonathan
Vesty, Sarah
Hadaki, Maher
Quigley, Mary
Doughty, Julie
Laws, Siobhan
Seetharam, Seema
Thorne, Amanda
Donnelly, Peter
- License Information
-
More Information
Article History
Received: 18 December 2015
Accepted: 19 September 2016
First Online: 9 November 2016
Competing interests
: J.R. is employed by Oncimmune. C.H. is a paid consultant to Genomic Health, M.D. is a paid consultant to Pfizer and NanoString. J.R. holds stock in Oncimmune and FaHRAS. C.H. received travel expenses from Novartis, and J.R. from Oncimmune, AstraZeneca, Bayer, Novartis and Syndax. J.R. received honoraria from AstraZeneca, Bayer and Amgen. J.R. receives research funding from Oncimmune, and M.D. from Novartis, AstraZeneca and Pfizer. J.R. holds patents from Oncimmune and is in the speakers’ bureau of AstraZeneca. The remaining authors declare no competing financial interests.
